Zimelidine: Difference between revisions
Content deleted Content added
m Date/fix the maintenance tags or gen fixes using AWB |
Baronde's book includes all the information contained in this article |
||
| Line 1: | Line 1: | ||
{{Refimprove|date=December 2007}} |
|||
{{Drugbox| |
{{Drugbox| |
||
|IUPAC_name = ''3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-yl-prop-2-en-1-amine'' |
|IUPAC_name = ''3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-yl-prop-2-en-1-amine'' |
||
| Line 18: | Line 17: | ||
| excretion = ? |
| excretion = ? |
||
| pregnancy_category = ? |
| pregnancy_category = ? |
||
| legal_status = |
| legal_status = Rx Only, Withdrawn worldwide |
||
| routes_of_administration= Oral |
| routes_of_administration= Oral |
||
}} |
}} |
||
{{Unreferencedsection|date=December 2007}} |
|||
'''Zimelidine''' ('''Normud®''', '''Zelmid®''') was the first |
'''Zimelidine''' ('''Normud®''', '''Zelmid®''') was the first [[selective serotonin reuptake inhibitor]] (SSRI) [[antidepressant]] to be marketed. It is a pyridylallylamine, and is structurally different from other antidepressants. <!--Barondes, Samuel H. "Better Than Prozac", pg. 39-40.--> |
||
Zimelidine was developed in the early [[1980s]] by [[Arvid Carlsson]], who was then working for the [[Sweden|Swedish]] company [[AstraZeneca|Astra AB]]. It was discovered following a search for drugs with structures similar to [[brompheniramine]] (it is a [[derivative (chemistry)|derivative]] of [[bromphenamine]]), an [[antihistamine]] with antidepressant activity. Zimelidine was first sold in [[1982]]. |
|||
Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as [[Guillain-Barré syndrome]] and due to a peculiar hypersensitivity reaction involving many organs including skin [[exanthem]]a, [[influenza|flu]]-like symptoms, [[arthralgia]]s, and sometimes [[eosinophilia]]. Additionally, zimelidine was charged to cause an increase in [[suicidal]] ideation and/or attempts among depressive patients. After its ban, it was succeeded by [[fluvoxamine]] and [[fluoxetine]] (derived from the [[antihistamine]] [[diphenhydramine]]) in that order, and the other SSRIs. |
Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as [[Guillain-Barré syndrome]] and due to a peculiar hypersensitivity reaction involving many organs including skin [[exanthem]]a, [[influenza|flu]]-like symptoms, [[arthralgia]]s, and sometimes [[eosinophilia]]. Additionally, zimelidine was charged to cause an increase in [[suicidal]] ideation and/or attempts among depressive patients. After its ban, it was succeeded by [[fluvoxamine]] and [[fluoxetine]] (derived from the [[antihistamine]] [[diphenhydramine]]) in that order, and the other SSRIs. |
||
== |
==Mechanism of action== |
||
The mode of action is a strong reuptake inhibition of [[serotonin]] from the synaptic cleft. Postsynaptic receptors are not acted upon. |
The mode of action is a strong reuptake inhibition of [[serotonin]] from the synaptic cleft. Postsynaptic receptors are not acted upon. |
||
== |
==Other uses== |
||
Zimelidine was reported by Montplaisir and Godbout to be very effective for [[cataplexy]] in 1986, back when this was usually controlled by [[tricyclic antidepressant]]s, which often had [[anticholinergic]] effects.{{ref|cataplexy}} Zimelidine was able to improve cataplexy without causing daytime sleepiness.{{ref|no_tired}} |
Zimelidine was reported by Montplaisir and Godbout to be very effective for [[cataplexy]] in 1986, back when this was usually controlled by [[tricyclic antidepressant]]s, which often had [[anticholinergic]] effects.{{ref|cataplexy}} Zimelidine was able to improve cataplexy without causing daytime sleepiness.{{ref|no_tired}} |
||
== |
==Side effects== |
||
Most often reported were: |
Most often reported were: |
||
| Line 46: | Line 44: | ||
* [[MAOIs|MAO inhibitors]] - severe or life-threatening reactions possible |
* [[MAOIs|MAO inhibitors]] - severe or life-threatening reactions possible |
||
== |
==Dosage== |
||
The former doses were 200 to 400mg daily in outpatients and up to 600mg in inpatients. |
The former doses were 200 to 400mg daily in outpatients and up to 600mg in inpatients. |
||
== |
==References== |
||
* [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=182628 PubChem Substance Summary: Zimelidine] National Center for Biotechnology Information. |
* [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=182628 PubChem Substance Summary: Zimelidine] National Center for Biotechnology Information. |
||
* Bruce G. Charlton, ''[http://www.hedweb.com/bgcharlton/sdtm.html Self-management of psychiatric symptoms using over-the-counter (OTC) psychopharmacology: the S-DTM therapeutic model - self-diagnosis, self-treatment, self-monitoring]''. ''Medical Hypotheses'' [[2005]]; 65: 823-828. |
* Bruce G. Charlton, ''[http://www.hedweb.com/bgcharlton/sdtm.html Self-management of psychiatric symptoms using over-the-counter (OTC) psychopharmacology: the S-DTM therapeutic model - self-diagnosis, self-treatment, self-monitoring]''. ''Medical Hypotheses'' [[2005]]; 65: 823-828. |
||
Revision as of 03:28, 22 April 2008
| File:Zimelidine.png | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Elimination half-life | 8.4 +/- 2.0 hours (parent compound) 19.4 +/- 3.6 hours (norzimelidine) |
| Excretion | ? |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H17BrN2 |
| Molar mass | 317.224 g·mol−1 |
Zimelidine (Normud®, Zelmid®) was the first selective serotonin reuptake inhibitor (SSRI) antidepressant to be marketed. It is a pyridylallylamine, and is structurally different from other antidepressants.
Zimelidine was developed in the early 1980s by Arvid Carlsson, who was then working for the Swedish company Astra AB. It was discovered following a search for drugs with structures similar to brompheniramine (it is a derivative of bromphenamine), an antihistamine with antidepressant activity. Zimelidine was first sold in 1982.
Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exanthema, flu-like symptoms, arthralgias, and sometimes eosinophilia. Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. After its ban, it was succeeded by fluvoxamine and fluoxetine (derived from the antihistamine diphenhydramine) in that order, and the other SSRIs.
Mechanism of action
The mode of action is a strong reuptake inhibition of serotonin from the synaptic cleft. Postsynaptic receptors are not acted upon.
Other uses
Zimelidine was reported by Montplaisir and Godbout to be very effective for cataplexy in 1986, back when this was usually controlled by tricyclic antidepressants, which often had anticholinergic effects.[1] Zimelidine was able to improve cataplexy without causing daytime sleepiness.[2]
Side effects
Most often reported were:
- Dry mouth, dryness of pharyngeal and nasal membranes
- Increased sweating (hyperhidrosis)
- Vertigo
- Nausea
Interactions
- MAO inhibitors - severe or life-threatening reactions possible
Dosage
The former doses were 200 to 400mg daily in outpatients and up to 600mg in inpatients.
References
- PubChem Substance Summary: Zimelidine National Center for Biotechnology Information.
- Bruce G. Charlton, Self-management of psychiatric symptoms using over-the-counter (OTC) psychopharmacology: the S-DTM therapeutic model - self-diagnosis, self-treatment, self-monitoring. Medical Hypotheses 2005; 65: 823-828.
- ^ Caille G, Kouassi E, de Montigny C. (1986). "Pharmacokinetic study of zimelidine using a new GLC method". Clinical Pharmacokinetics. 8 (6): 530–40. PMID 6228368.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Godbout R, Montplaisir J. (1986). "The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients". Clinical Neuropharmacology. 9 (1): 46–51. PMID 2950994.
- ^ see Godbout et al. 1986